The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
The conversation is a satirical discussion about a baby with hair loss using adult hair loss treatments like finasteride, minoxidil, and ketoconazole, as well as dermarolling, scalp massages, and plans for PRP sessions. Suggestions include various other treatments and humorous advice, reflecting the satire of the situation.
The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.
A user is starting treatment for hair loss with topical minoxidil, oral finasteride, and is considering adding topical latanoprost but is unsure about the application frequency and method for latanoprost. They are seeking advice from others with experience using these treatments.
Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.
The conversation humorously discusses hair loss and subtle differences in hairlines, with references to Norwood scale stages. It satirizes the idea of asking AI for hair advice.
The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
A new product, Minoxidil booster, which enhances sulfotransferase enzyme activity in the scalp, is now available. The user has started using this product, applied before Minoxidil, to improve their hair loss treatment results.
Mixing Nizoral and T-Gel in a 1:1 ratio and using it three times a week provided relief from persistent seborrheic dermatitis. This treatment is recommended for those with stubborn SD.
The conversation humorously critiques hair loss treatments and the subreddit r/tressless. It mentions Minoxidil and finasteride as common treatments, with users reacting to a satirical roast by ChatGPT.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
The conversation humorously discusses hair loss treatments like finasteride and minoxidil, noting minoxidil's toxicity to cats. It jokes about a lion needing hair restoration, with references to hair transplants in Turkey.
The user experienced negative side effects from saw palmetto, including low libido and energy, and found some improvement after using Maca and Acetyl L-Carnitine. They emphasize lifestyle changes and positivity for recovery, while expressing caution about saw palmetto's side effects.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
An Instagram account named "hair_grwow" is stealing progress pictures from a subreddit and falsely claiming the results are due to their products. Users are upset and reporting the account, with one deciding to stop sharing their progress due to the theft.
A user received a prescription for Dutasteride 0.5 in Europe and asked about the brand. Replies confirmed the brand's quality and suggested using the cheapest gelatin capsule form.
The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.
Actor Patrick Stewart's success despite having a receding hairline, how hair loss may not be as crippling as it is perceived to be, and how different people are attracted to different physical features.